Fiber selectivity of peripheral neuropathy in patients with Parkinson's disease

Acta Neurol Scand. 2022 Jul;146(1):75-81. doi: 10.1111/ane.13624. Epub 2022 Apr 24.

Abstract

Objective: To determine the function of each type of peripheral nerve fiber and investigate the possible role of levodopa (LD) in peripheral neuropathy (PN) in Parkinson's disease (PD) patients.

Methods: We enrolled 60 patients with idiopathic PD. All PD patients were divided into three groups: levodopa exposure >3 years (LELD), levodopa exposure ≤3 years (SELD) and de novo patients with PD (NOLD). The current perception threshold (CPT), which was measured by Neurometer at 2000, 250 and 5 Hz, the level of homocysteine, Vitamin B12 and folic acid in plasma, were compared with those of sex- and age-matched healthy controls (HCs).

Results: Current perception threshold was higher at 250 Hz (p < .05) and 5 Hz (p < .05) in the LELD group than the NOLD, SELD, and control group. CPT was lower at 5 Hz in the NOLD than in the HCs group (p < .05). The CPT of the more affected side of PD patients was positively correlated with H-Y stage at 5 Hz current stimulation (r = .42, p = .01). Multivariate logistic regression analysis showed that elevated homocysteine levels were the risk factor of sensory nerve injury in PD patients (p < .01). Serum homocysteine levels were positively correlated with levodopa (LD) daily dose, LD equivalent daily dose, and LD cumulative lifetime dose (p < .05).

Conclusions: Peripheral neuropathy in PD patients can occur in the early stage of PD exhibiting as hyperesthesia and is fiber selectivity, especially for Aδ and C nerve fibers. PN in PD patients is related to PD itself and long-term LD exposure. Elevated plasma homocysteine is a risk factor for PN in PD patients.

Keywords: Parkinson's disease; fiber selectivity; levodopa; peripheral neuropathy.

MeSH terms

  • Antiparkinson Agents / adverse effects
  • Homocysteine
  • Humans
  • Levodopa / adverse effects
  • Parkinson Disease* / complications
  • Parkinson Disease* / drug therapy
  • Peripheral Nervous System Diseases* / chemically induced

Substances

  • Antiparkinson Agents
  • Homocysteine
  • Levodopa